Search

Your search keyword '"Han, J.-Y."' showing total 1,379 results

Search Constraints

Start Over You searched for: Author "Han, J.-Y." Remove constraint Author: "Han, J.-Y." Language english Remove constraint Language: english
1,379 results on '"Han, J.-Y."'

Search Results

1. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

3. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

6. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

7. High-precision measurement of the W boson mass with the CDF II detector

13. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

19. High-precision measurement of the W boson mass with the CDF II detector

21. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

27. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

33. Measurement of the charge asymmetry of electrons from the decays of W bosons produced in pp̅ collisions at √s =1.96 TeV

34. Measurement of the charge asymmetry of electrons from the decays of W bosons produced in $\overline{pp}$ collisions at $\sqrt{s}$ =1.96 TeV

36. Search for scalar top quark production in $ \sqrt{s}=1.96\;\mathrm{TeV} $

38. 1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

39. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A

41. Improved determination of the sample composition of dimuon events produced in $\sqrt{s}=1.96$ TeV

42. Comments and Reply on: “Study of multi-muon events produced in $\sqrt{s}=1.96$ TeV”; T. Aaltonen et al. (The CDF Collaboration)

43. Study of multi-muon events produced in $\sqrt{s}=1.96$ TeV

46. Search for narrow resonances lighter than ϒ mesons

47. INTEGRATING INSAR INFORMATION AND SPATIAL-TEMPORAL FACTORS IN MACHINE LEARNING ANALYSIS FOR LANDSLIDE PREDICTION – A CASE STUDY FOR PROVINCIAL HIGHWAY 18 AREA IN TAIWAN.

50. Tumour necrosis factor [alpha] signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice

Catalog

Books, media, physical & digital resources